Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

6.500 -0.280 (-4.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,319,986
Open 6.900
Bid (Size) 6.200 (1)
Ask (Size) 6.450 (10)
Prev. Close 6.780
Today's Range 6.210 - 7.000
52wk Range 1.775 - 7.070
Shares Outstanding 121,613,181
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week
The cancer-focused biotech has a bright future, according to one pundit. 
Via The Motley Fool
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
From Relay Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+51.2%
+51.2%
1 Month
+59.7%
+59.7%
3 Month
+74.3%
+74.3%
6 Month
+192.8%
+192.8%
1 Year
+1.4%
+1.4%

More News

Read More
Medtronic To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Relay (RLAY) Q2 Loss Narrows 41%
Via The Motley Fool
Topics Intellectual Property
Earnings Scheduled For August 7, 2025
Via Benzinga
Preview: Relay Therapeutics's Earnings
Via Benzinga
Earnings Scheduled For February 26, 2025
Via Benzinga
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Relay Therapeutics, Inc. - Common Stock publicly traded?
Yes, Relay Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Relay Therapeutics, Inc. - Common Stock trade on?
Relay Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Relay Therapeutics, Inc. - Common Stock?
The ticker symbol for Relay Therapeutics, Inc. - Common Stock is RLAY on the Nasdaq Stock Market
What is the current price of Relay Therapeutics, Inc. - Common Stock?
The current price of Relay Therapeutics, Inc. - Common Stock is 6.500
When was Relay Therapeutics, Inc. - Common Stock last traded?
The last trade of Relay Therapeutics, Inc. - Common Stock was at 10/10/25 04:00 PM ET
What is the market capitalization of Relay Therapeutics, Inc. - Common Stock?
The market capitalization of Relay Therapeutics, Inc. - Common Stock is 790.49M
How many shares of Relay Therapeutics, Inc. - Common Stock are outstanding?
Relay Therapeutics, Inc. - Common Stock has 790M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.